|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0024 - 0.0028|
|52 Week Range||0.0003 - 0.0059|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PAO Group, Inc. (USOTC: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).
Sandusky, Ohio--(Newsfile Corp. - September 24, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR ...
HOLLYWOOD, CA / ACCESSWIRE / September 18, 2020 / Credit and wealth, cannabis cultivation, solar, nutrition, savage acts; this week on MoneyTV with Donald Baillargeon.